Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 11/09/2024			5-day change	1st Jan Change
38.99 ^CNY	+0.49%		-1.29%	-25.94%

09-06	Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares.	CI
09-05	Gan & Lee Pharmaceuticals. authorizes a Buyback Plan.	CI

Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..

June 13, 2023

Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals. (SHSE:603087) on June 14, 2023. Endogenix generated a revenue of RUB 4.6 million last year.

Pharmaktiv completed the acquisition of remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals. (SHSE:603087) on June 14, 2023.

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares.	09-05	CI
Gan & Lee Pharmaceuticals. authorizes a Buyback Plan.	09-04	CI
Gan & Lee Pharmaceuticals' H1 Profit Soars 123%; Shares Jump 4%	08-29	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2024	08-28	CI
Gan & Lee Pharmaceuticals' Unit Secures Nod to Trial Insulin Injection in US	08-06	MT
Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index	06-16	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index	06-16	CI
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	05-24	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	01-26	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12-12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	12-04	MT
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	11-09	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12/10/23	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18/09/23	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18/09/23	CI
Gan & Lee Pharma Advances Trial of New Insulin Product	13/09/23	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20/07/23	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20/06/23	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	13/06/23	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI

Chart Gan & Lee Pharmaceuticals.

Duration

Period

More charts

Company Profile

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

4,482

Sector

Pharmaceuticals

Calendar

29/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company